Literature DB >> 10833216

The prospects for red-cell substitutes.

H G Klein.   

Abstract

Mesh:

Substances:

Year:  2000        PMID: 10833216     DOI: 10.1056/NEJM200006013422211

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Influence of the chemistry of conjugation of poly(ethylene glycol) to Hb on the oxygen-binding and solution properties of the PEG-Hb conjugate.

Authors:  Tao Hu; Muthuchidambaram Prabhakaran; Seetharama A Acharya; Belur N Manjula
Journal:  Biochem J       Date:  2005-12-15       Impact factor: 3.857

2.  Extension arm facilitated PEGylation of hemoglobin: correlation of the properties with the extent of PEGylation.

Authors:  Dongxia Li; Belur N Manjula; A Seetharama Acharya
Journal:  Protein J       Date:  2006-06       Impact factor: 2.371

3.  Influence of intramolecular cross-links on the molecular, structural and functional properties of PEGylated haemoglobin.

Authors:  Tao Hu; Belur N Manjula; Dongxia Li; Michael Brenowitz; Seetharama A Acharya
Journal:  Biochem J       Date:  2007-02-15       Impact factor: 3.857

4.  Non-hypertensive tetraPEGylated canine haemoglobin: correlation between PEGylation, O2 affinity and tissue oxygenation.

Authors:  Seetharama A Acharya; Vivek N Acharya; Nirmala Devi Kanika; Amy G Tsai; Marcos Intaglietta; Belur N Manjula
Journal:  Biochem J       Date:  2007-08-01       Impact factor: 3.857

5.  A novel nanobiotherapeutic poly-[hemoglobin-superoxide dismutase-catalase-carbonic anhydrase] with no cardiac toxicity for the resuscitation of a rat model with 90 minutes of sustained severe hemorrhagic shock with loss of 2/3 blood volume.

Authors:  Yuzhu Bian; Thomas Ming Swi Chang
Journal:  Artif Cells Nanomed Biotechnol       Date:  2014-10-09       Impact factor: 5.678

6.  Delayed gastric emptying in critical illness: is enhanced enterogastric inhibition with cholecystokinin and peptide YY involved?

Authors:  Andrew J W Samis
Journal:  Crit Care Med       Date:  2008-05       Impact factor: 7.598

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.